Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Multicenter, Observer-Blinded, Randomized, Active Controlled, Immune Non-inferiority and Safety Study of Vi-DT Vaccine Compared to Typbar TCV® in Healthy 6 Months-45 Years Aged Nepalese Participants.

NCT03933098 is registered in ClinicalTrials.gov with International Vaccine Institute as lead sponsor.

NCT NCT03933098
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03933098 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Multicenter, Observer-Blinded, Randomized, Active Controlled, Immune Non-inferiority and Safety Study of Vi-DT Vaccine Compared to Typbar TCV® in Healthy 6 Months-45 Years Aged Nepalese Participants.
Lead sponsor
International Vaccine Institute
Phase
Phase 3
Overall status
Unknown status
Start date
November 15, 2019
Completion date
January 31, 2021
Enrollment
1,800 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

typhoid